SCHEMBL496064

SCHEMBL496064

CC1(C)CC(Nc2cc(Cl)ccc2C#N)CC(C)(C)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 1/20 0.45
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EZH2 Q15910 9/20 0.42
PKM P14618 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
RAD52 P43351 1/20 0.40
GFER P55789 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
AR P10275 1/20 0.37
HTT P42858 1/20 0.37
NOS3 P29474 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471326 0.81 KMT2A (0.47) MEN1KMT2AMAPK1SMN1; SMN2PKM
SCHEMBL495787 0.80 NOS2 (0.40) MEN1KMT2AEZH2ALDH1A1LMNA
SCHEMBL1471325 0.79 KMT2A (0.47) MEN1KMT2AMAPK1SMN1; SMN2PKM
SCHEMBL495856 0.77 MEN1 (0.48) MEN1KMT2AMAPK1ALDH1A1LMNA
SCHEMBL1471475 0.76 PKM (0.46) MEN1KMT2AMAPK1SMN1; SMN2PKM
SCHEMBL22093103 0.76 MEN1 (0.47) MEN1KMT2AMAPK1MAPTL3MBTL1
Hydrochloric Acid SCHEMBL1470849 0.75 PKM (0.45) MEN1KMT2AMAPK1SMN1; SMN2PKM
Fumaric Acid SCHEMBL1470857 0.72 MEN1 (0.47) MEN1KMT2AMAPK1SMN1; SMN2EZH2
SCHEMBL15025471 0.71 NOS3 (0.39) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL7793247 0.70 KMT2A (0.59) MEN1KMT2AMAPK1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
CN-101312720-A 2-aminobenzamide derivative ASTELLAS PHARMA INC (JP) 2008-11-26 CN disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 PRKCQ 4776/4885MEN1 3066/4885KMT2A 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.